BioWorld Science: The Daily Drug R&D News Source
WEBEnjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription. Daily news focused on drug discovery, delivery and preclinical research. Coverage includes: Congress highlights, key studies from peer-reviewed journals, chemical structure images, pharmacology ...
FDA nod for ABM Respiratory Care’s Biwaze Cough system
WEBApr 1, 2020 · Charleston, S.C.-based startup ABM Respiratory Care has received U.S. FDA clearance for its first product, an airway clearance system known as Biwaze Cough. The portable device helps to remove secretions for people who are unable to cough or clear away secretions effectively on their own due to injury or disease. ABM – which stands for Advanced Bio Machines – based its 510(k) for Biwaze ...
| BioWorld
WEBMay 1, 2003 · BioWorld MedTech. Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product …
Getinge to acquire Paragonix for $477M | BioWorld
WEBAug 23, 2024 · Getinge AB agreed to acquire Paragonix Technologies Inc. for $477 million, including upfront and earn out payments. The deal marks Getinge’s entry into the global organ preservation and transportation market, a rapidly advancing field driven by rising transplant volumes, technological innovations and evolving clinical practices.
Novo Nordisk wins first FDA approval for long-acting human
WEBSep 1, 2020 · The first weekly therapy for adult growth hormone deficiency (GHD) has arrived in the U.S. with FDA approval for Novo Nordisk A/S' Sogroya (somapacitan). It’s the first of Novo's regulatory filings for the medicine, also submitted in the EU and Japan, to win approval. Growth hormone deficiency is characterized by inadequate growth hormone production from the anterior pituitary gland.
Elise Mak - BioWorld
WEBJul 15, 2021 · Biogen catches up in MS with nearly $1B deal for Innocare’s orelabrutinib. July 13, 2021. By Elise Mak. No Comments. In a deal that could be worth up to $937.5 million, Biogen Inc. licensed rights to phase II-stage, brain-penetrant BTK inhibitor orelabrutinib from Innocare Pharma Ltd. for the treatment of multiple sclerosis (MS) and ...
US FDA expands guidance on race, ethnicity data in trials
WEBJan 29, 2024 · In keeping with federal standards for classifying race and ethnicity data, the U.S. FDA issued a draft revision to broaden its 2016 guidance on the collection of such data in clinical trials. Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping ...
mRNA vaccine could prevent and treat HPV-related cancer
WEBApril 3, 2024. A group of scientists at Shanghai Virogin Biotech Co. and Zhujiang Hospital in China designed a new mRNA vaccine that could prevent tumor formation associated with human papillomavirus 16 (HPV16) and also reduce its size if used as a treatment. BioWorld Science Drug design, drug delivery and technologies Vaccines Cancer Immune ...
BBO-10203 inhibits RAS-driven PI3Kα activity in tumor cells
WEBDec 27, 2023 · Researchers from Bridgebio Pharma Inc. recently presented BBO-10203, a first-in-class, orally bioavailable, covalent small-molecule candidate designed to inhibit RAS-driven PI3Kα activity without affecting glucose metabolism.
Patents - Page 2 | BioWorld
WEB3 days ago · Sep. 10, 2024. No Comments. New miR-124 activators have been reported in a recent Nanjing Synnocare Pharmaceutical Technology Co. Ltd. patent as potentially useful for the treatment of Alzheimer type dementia, Parkinson’s disease, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, cancer and viral infections. Read More.